Welcome to our dedicated page for Bioventus news (Ticker: BVS), a resource for investors and traders seeking the latest updates and insights on Bioventus stock.
Bioventus Inc. (Nasdaq: BVS) is a medical technology company that describes itself as a global leader in innovations for active healing. The Bioventus news stream features company announcements, financial updates and product milestones that reflect its focus on Pain Treatments, Surgical Solutions and Restorative Therapies.
Investors following BVS news will find regular earnings releases where Bioventus reports net sales, segment performance across Pain Treatments, Surgical Solutions and Restorative Therapies, and metrics such as net income, Adjusted EBITDA and non-GAAP earnings. These updates often include commentary on organic revenue trends, portfolio changes like the divestiture of the Advanced Rehabilitation Business, and the impact of factors such as foreign currency and tariffs.
The company also issues product and regulatory news, including announcements of U.S. Food and Drug Administration (FDA) 510(k) clearances. Recent examples include clearances for TalisMann and StimTrial, two Peripheral Nerve Stimulation products for chronic pain management that Bioventus highlights as expanding its non-opioid, minimally invasive therapy portfolio.
Bioventus news items cover capital structure and financing developments, such as the entry into a new senior secured credit agreement that refinanced prior debt, increased revolving capacity and reduced interest margins. In addition, the company regularly announces participation in major healthcare and investor conferences hosted by firms such as J.P. Morgan, Piper Sandler, Morgan Stanley and Canaccord Genuity.
For readers tracking BVS, the news page provides a centralized view of Bioventus’ financial performance, product pipeline progress, regulatory milestones and corporate events, helping contextualize how its Pain Treatments, Surgical Solutions and Restorative Therapies businesses evolve over time.
Bioventus (Nasdaq: BVS) reported fourth-quarter 2025 revenue of $157.9M (reported +2.8%, organic +10.0%) and full-year revenue of $568.1M (reported -0.9%, organic +7.5%).
Q4 GAAP EPS was $0.21; FY GAAP EPS was $0.33. Adjusted EBITDA grew to $116.3M for 2025. 2026 guidance: net sales $600–610M, adjusted EPS $0.73–0.77, and cash from operations $82–87M.
Bioventus (Nasdaq: BVS) will report fourth-quarter fiscal 2025 results before the market opens on March 5, 2026.
Management will host a conference call at 8:30 a.m. Eastern Time that day. According to Bioventus, investors can dial 1-833-636-0497 or join a live webcast and view materials at the company’s Investor Relations site. The webcast will be archived and available for replay through March 4, 2027.
Bioventus (Nasdaq: BVS) announced that CEO Rob Claypoole will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 9:45 a.m. PT / 12:45 p.m. ET.
The presentation will be available via live webcast on the company's Investors website and will be available for replay through February 14, 2026. The webcast will include a Q&A session.
Bioventus (Nasdaq: BVS) announced that Rob Claypoole, President and CEO, will present at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 10:10 a.m. ET.
A live webcast of the presentation and a following Q&A will be available on the company’s Investors webpage at www.bioventus.com, with a replay posted after the event.
Bioventus (NASDAQ: BVS) reported Q3 2025 revenue of $138.7M with organic revenue +8.2% and reported revenue down 0.2% versus prior year due to a prior-year divestiture. GAAP EPS was $0.05 versus a prior-year loss of $0.08; Non-GAAP EPS was $0.15 (+200%). Adjusted EBITDA was $26.6M (+12.9%) with a 19.2% margin (+220 bps). Cash from operations was $30.1M (+192%). The company reaffirmed full-year 2025 guidance: net sales $560M–$570M, Adjusted EBITDA $112M–$116M, and Non-GAAP EPS $0.64–$0.68.
Bioventus (Nasdaq: BVS) will report third quarter fiscal 2025 financial results before the market opens on Tuesday, November 4, 2025.
Management will host a conference call at 8:30 a.m. Eastern Time the same day. Investors can dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call, or join a live webcast and view accompanying materials on the company Investor Relations website at https://ir.bioventus.com/. The webcast will be archived and available for replay through November 3, 2026.
Bioventus (Nasdaq: BVS), a global leader in innovations for active healing, has announced its participation in the upcoming Morgan Stanley Global Healthcare Conference. Mark Singleton, the company's Senior Vice-President and Chief Financial Officer, will engage in a fireside chat on September 10, 2025, at 1:05 p.m. ET.
Investors can access a live webcast of the presentation through the "Investors" section of Bioventus's website at www.bioventus.com, with a replay option available after the event.
Bioventus (Nasdaq: BVS), a global leader in innovations for active healing, has announced its participation in the upcoming Canaccord Genuity Global Growth Conference. Rob Claypoole, the company's President and CEO, will engage in a fireside chat on Tuesday, August 12, 2025, at 2:00 p.m. ET.
The presentation will include a question-and-answer session and will be accessible via live webcast through the "Investors" section of Bioventus's website. A replay of the event will be made available on the company's website following the presentation.
Bioventus (Nasdaq: BVS) reported Q2 2025 financial results with revenue of $147.7 million, showing a 2.4% decline but 6.2% organic growth. The company achieved diluted EPS of $0.11 compared to a loss of $0.40 in the prior year, while non-GAAP EPS grew 31% to $0.21.
Key highlights include FDA clearance for TalisMann and StimTrial for chronic peripheral nerve pain treatment, representing a $2 billion market opportunity. The company's segments showed mixed performance: Pain Treatments grew 1.5% to $73.3M, Surgical Solutions increased 11.4% to $52.7M, while Restorative Therapies declined 31.6% to $21.6M due to business divestiture.
Bioventus reiterated its 2025 guidance with expected revenue of $560-570 million and non-GAAP EPS of $0.64-0.68.
Bioventus (Nasdaq: BVS) has secured a new $400 million Senior Secured Credit Agreement, comprising a $300 million term loan and a $100 million revolving credit facility, maturing on July 31, 2030. The agreement represents significant improvements over their 2019 Credit Agreement, featuring a 75 basis point reduction in interest margin, generating over $2 million in annual interest savings.
Key enhancements include an increase in revolving credit facility from $40 million to $100 million, and a reduction in annual term loan amortization from 10% to 5%. The company used the proceeds to repay its outstanding $333 million loan balance under the 2019 agreement, utilizing the new term loan, $30 million from the revolving facility, and $3 million cash on hand.